- Home
- INTU vs AMGN Comparison
INTU vs AMGN Comparison
Compare INTU & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | AMGN |
|---|---|---|
| Founded | 1983 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7B | 181.7B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | INTU | AMGN |
|---|---|---|
| Price | $566.53 | $328.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 14 |
| Target Price | ★ $799.32 | $321.69 |
| AVG Volume (30 Days) | 1.7M | ★ 2.8M |
| Earning Date | 02-24-2026 | 02-03-2026 |
| Dividend Yield | 0.79% | ★ 3.11% |
| EPS Growth | 41.77 | ★ 65.12 |
| EPS | ★ 14.57 | 12.93 |
| Revenue | $19,433,000,000.00 | ★ $35,971,000,000.00 |
| Revenue This Year | $14.85 | $10.85 |
| Revenue Next Year | $12.46 | $1.77 |
| P/E Ratio | $41.53 | ★ $25.07 |
| Revenue Growth | ★ 17.14 | 10.56 |
| 52 Week Low | $532.65 | $261.28 |
| 52 Week High | $813.70 | $346.38 |
Technical Indicators
Market Signals| Indicator | INTU | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 23.60 | 50.40 |
| Support Level | $619.70 | $319.79 |
| Resistance Level | $657.81 | $343.05 |
| Average True Range (ATR) | 17.28 | 6.64 |
| MACD | -8.42 | -0.54 |
| Stochastic Oscillator | 9.50 | 40.54 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.